Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors

This study is testing a new therapeutic vaccine called TI-0093 in people with cancers caused by HPV-16 (a strain of the human papillomavirus) that have returned or spread, including cancers of the head and neck, cervix, and other sites. The vaccine is designed to train the immune system to recognize and destroy HPV-16-infected cancer cells. **You may be eligible if...** - You are between 18 and 75 years old with confirmed HPV-16 positive cancer - Your cancer is recurrent or metastatic and has progressed after standard treatment options - You are in good general health (ECOG 0–1) and have at least one measurable tumor - Your blood counts, liver, kidney, and heart function meet required thresholds **You may NOT be eligible if...** - You have previously received an HPV vaccine for therapeutic purposes - You have active brain metastases, recent major surgery, deep vein clots, or active bleeding - You have active autoimmune disease, serious heart conditions, uncontrolled diabetes, or active infections (including HIV, hepatitis B, hepatitis C, or tuberculosis) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.